High-grade glioma (HGG) is the most common type of primary brain tumour in adults and accounts for >75% of the estimated 22,070 newly diagnosed malignant primary brain tumours in the US each year.
III study conducted by the European Organisation for Research and
Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) in newly diagnosed GBM comparing RT alone (60Gy over six weeks) with RT and concomitant daily temozolomide (75mg/m 2 /day), followed by adjuvant temozolomide therapy (150-200mg/m 2 /day for five consecutive days every 28-day cycle, for six cycles). 16 The addition of temozolomide to RT increased median survival compared with RT alone (14.6 versus 12.1 months; p<0.0001). Recently, updated results from this study showed that the added survival benefit with temozolomide was maintained, even at five years. 25 An established mechanism of temozolomide resistance is based on DNA repair through O-6-methylguanine-DNA methyltransferase (MGMT), an endogenous DNA-repair enzyme that removes alkyl groups from DNA and thus confers resistance to temozolomide and other alkylating agents. MGMT promoter methylation has been shown to predict temozolomide sensitivity in GBM. 6, 26 In a companion study to the EORTC/NCIC, tumour specimens were evaluated for methylation status of the MGMT gene promoter. 6 As predicted, the benefit of temozolomide was significantly increased in patients with MGMT promoter methylation. Among GBM patients with MGMT promoter methylation who were treated with temozolomide, median survival was 21.7 months and two-year survival 46%.
Temozolomide-treated patients with unmethylated MGMT promoters had a significantly shorter median survival of only 12.7 months and a two-year survival of 13.8%. 6 Because this study was conducted retrospectively in a relatively small sample of patients, temozolomide remains the standard of care for newly diagnosed GBM patients, regardless of MGMT promoter methylation status. A randomised phase III trial sponsored by the Radiation Therapy Oncology Group (RTOG 0525) will definitively evaluate the utility of MGMT promoter methylation in determining temozolomide sensitivity. In the future, patients whose tumours have unmethylated MGMT promoters may be offered alternatives to the standard temozolomide regimen.
Investigational approaches to overcome MGMT activity include dose-intense temozolomide regimens 27, 28 or continuous dosing, 29 which may deplete the enzyme, 30 and combination therapy with O6-benzylguanine or other MGMT inhibitors. [31] [32] [33] An alternative to systemic chemotherapy involves the surgical implantation of carmustine-containing biodegradable wafers (Gliadel) into the resection cavity following tumour debulking. A double-blind, randomised, phase III trial demonstrated a modest benefit in patients with newly diagnosed GBM. Those patients who received radiation and placebo had a median survival of only 11.6 months compared with 13.9 months for patients who received radiation and carmustine wafers, with median overall survival of 11.6 and 13.9 months, respectively (p=0.03), 34 resulting in approval of this therapy by the US Food and Drug Administration (FDA). The benefits of traditional cytotoxic chemotherapy have been modest in the treatment of recurrent GBM.
Phase II trials of temozolomide for recurrent GBM demonstrated radiographic response rates (RR) of only 5% and six-month progressionfree survival (PFS6) of about 21%. 35, 36 However, the recently published RESCUE study showed that continuous dosing of temozolomide at 50mg/m 2 daily rather than the conventional 5/28 schedule had favourable efficacy and was well-tolerated as a second-line agent. 29 Other agents, such as carmustine, carboplatin, etoposide, irinotecan and procarbazine, lomustine (CCNU) and vincristine (PCV), produce low response rates and no significant survival benefit. 37 In Bevacizumab monotherapy was well-tolerated with a low incidence of intracranial haemorrhage (0-2.4%) and thromboembolism The previous practice of combining other cytotoxic agents, such as lomustine, carboplatin and etoposide, with bevacizumab for recurrent GBM that progresses despite bevacizumab and irinotecan has recently been challenged by a study that showed that these 
Chemotherapy for Anaplastic Glioma
Due to the paucity of randomised clinical trials, there is no consensus in terms of treatment of newly diagnosed anaplastic gliomas (AGs). The recent Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide (NOA-04) that randomised patients with AG to initial radiation followed by chemotherapy (temozolomide or PCV) at progression or initial chemotherapy followed by radiation at progression showed no difference in PFS between the two groups, regardless of histology. Tumours with oligodendroglial components, including anaplastic oligodendrogliomas (AO) and anaplastic oligoastrocytomas (AOAs), are less common than AA. However, they have a better prognosis than pure astrocytic tumours and may have increased sensitivity to treatment. 43 The majority of AOs and 14-20% of AOAs have deletions of chromosomes 1p and 19q 43 due to an unbalanced translocation of 19p to 1q. 44 Tumours with 1p/19q co-deletion are particularly sensitive to PCV chemotherapy 4, 45 and likely have sensitivity to temozolomide, with an increase in response rate from 34 to 59% in one study. 26 The value of PCV chemotherapy in combination with RT for newly diagnosed AO/AOA has been evaluated in two large phase III trials. 46, 47 Although neither study showed an overall survival benefit, patients treated with both RT and PCV chemotherapy had 10-12 months of additional PFS compared with RT alone. As previously mentioned, the NOA-04 trial that randomised AG patients to initial radiation or to initial chemotherapy (PCV or temozolomide) did not demonstrate a difference in PFS, regardless of treatment. 42 In all of these studies, 1p/19q co-deletion and MGMT status were associated with marked survival prolongation.
As most published studies in AO/AOA were initiated prior to 2005, the majority of available data involve PCV chemotherapy. Although the NOA-04 study was not powered to directly compare PCV and temozolomide, no PFS difference was observed between patients randomised to initial PCV versus initial temozolomide, 42 although temozolomide may be associated with less toxicity than PCV.
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Several large intergroup trials are under way evaluating the optimal combination of RT and temozolomide in patients with newly diagnosed AO/AOA.
Experimental Therapies
Targeted Molecular Therapies Figure 1 is a schematic of these pathways.
Advances in Treatment Options for High-grade Glioma 
Anti-angiogenic Therapies Vascular Endothelial Growth Factor Pathway Inhibitors
Angiogenesis is important to the growth and proliferation of HGG and is mediated through several pathways, most notably VEGF. [49] [50] [51] Higher levels of VEGF expression are observed in more malignant tumours.
Targeting VEGF and VEGFR has been the focus of many recent clinical trials. As noted above, bevacizumab has shown promising activity in recurrent GBM and is now FDA-approved for this indication. 40, 52, 53 Phase II studies of bevacizumab plus irinotecan have also demonstrated efficacy in AG with an RR of 55-66% and PFS6 of 56-61%. 54, 55 Bevacizumab is generally well-tolerated, with the most common side effects being fatigue, hypertension and proteinuria.
Less common serious side effects include thromboembolism, haemorrhage and bowel perforation.
There is emerging evidence that inhibitors of angiogenesis may work synergistically with RT. 21 Two large multicentre trials evaluating the efficacy of adding bevacizumab to RT and temozolomide in newly diagnosed GBM patients are under way. Phase II studies of the regimen appear to be safe despite a possible increase in woundhealing complications. 56 Treatment of HGG with bevacizumab combined with a variety of targeted molecular agents is being studied as well.
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Another VEGF-pathway inhibitor currently in clinical trials for HGG is aflibercept (a VEGF decoy receptor that consists of a VEGF receptor fused to an immunoglobulin constant region). 57 In addition to inhibitors of VEGF such as bevacizumab and aflibercept, there are many smallmolecule TKIs directed against VEGFR. Cediranib is an oral pan-VEGFR inhibitor that also has activity against platelet-derived growth factor (PDGFR) and c-Kit. In a phase II clinical trial for recurrent GBM, cediranib achieved a promising RR of 27% and PFS6 of 26%. 58 As had been noted in the bevacizumab studies, there was a striking steroid-sparing effect, and the drug was well-tolerated. Other multitargeted VEGFR agents include vandetanib (VEGFR and EGFR), sorafenib (VEGFR, Raf, c-Kit), sunitinib (VEGFR-2, PDFR, c-kit and Flt-3), pazopanib (VEGFR, PDGFR, c-Kit), XL184 (VEGFR and c-Met) and CT322. 59 Unfortunately, the benefits of anti-angiogenesis therapy are transitory, and it has been suggested that the impressive radiographic responses observed in patients treated with bevacizumab may be the result of decreased permeability of the vasculature rather than a true antitumour effect (see Figure 2) . Mechanisms of resistance to anti-angiogenic therapy are beginning to be elucidated. Working Group recently proposed updated response criteria for HGG. 71 In addition, levels of basic fibroblast growth factor (bFGF) and stromalderived growth factor 1 alpha (SDF-1α) increase in GBM patients when tumours escaped treatment with cediranib. 72 These findings imply that one may overcome resistance to anti-angiogenic agents by combining anti-VEGF/VEGFR therapy with agents that target tumour invasion, non-VEGF-pro-angiogenic signalling pathways such as the FGF pathway or vasculogenic pathways such as the SDF-1α pathway.
Integrins
The αvβ3 and αvβ5 integrins are cell-surface receptors that promote endothelial cell migration and survival during angiogenesis. 73 Cilengitide (EMD121974) competitively inhibits αvβ3 and αvβ5. Phase II trials showed a PFS6 of 15% and a median OS of 9.9 months when cilengitide was added to RT and temozolomide. Patients with methylated MGMT promoter had better responses. 74 Based on the favourable results of this trial, a multicentre phase III trial is under way using cilengitide in patients with newly diagnosed GBM with methylated MGMT promoter.
Receptor Tyrosine Kinases

Epidermal Growth Factor Receptor Inhibitors
EGFR is the most commonly altered RTK in HGG. 75 Approximately
20-30% of GBM have a constitutively active EGFR mutant known
as EGFRvIII, and all of these EGFRvIII-expressing tumours also exhibit EGFR amplification or overexpression. 76 Signalling through these and other growth factor receptors activates fundamental signal transduction pathways such as the Ras/mitogen-activated protein kinase (MAPK) pathway and the PI3K/Akt/mTOR pathway, both of which promote cell proliferation. 10 Additionally, many of these pathways upregulate VEGF. 49, 77 While subsets of GBM patients have sustained responses to reversible
TKIs that target EGFR, to date the studies have been largely
Figure 2: 56-year-old Woman with Left Parietal Glioblastoma Showing Response to Therapy with XL184
XL184 is a vascular endothelial growth factor receptor and Met inhibitor. A: Axial T1 with contrast before therapy; B: Axial fluid-attenuated inverse recovery (FLAIR) before therapy; C: Axial T1 with contrast four weeks after therapy showing partial response; D: Axial FLAIR four weeks after therapy showing significant reduction in peritumoral oedema.
A B C D 94 However, since patients were required to have gross total resections and EGFRvIII mutation in order to be eligible for the trial, they represent a highly selected group with good prognosis.
Platelet-derived Growth Factor
Platelet-derived growth factors (PDGF) are a pleiotropic family of peptides that signal through PDGFR to stimulate cellular functions including growth, proliferation and differentiation. 95 Imatinib mesylate (Gleevec), an inhibitor of PDGFR-α and β, Bcr-Abl, c-Fms and c-Kit tyrosine kinases, demonstrated activity in pre-clinical models of glioma. 96 However, in clinical trials neither imatinib monotherapy 97, 98 nor imatinib in combination with hydroxyurea (a ribonucleoside diphosphate reductase inhibitor) 99 has demonstrated clinically useful activity in GBM. One explanation for the lack of efficacy is that imatinib is a substrate for the P-glycoprotein efflux pump that limits its intracranial distribution. 100 Tandutinib and dasatinib, secondgeneration PDGFR inhibitors with improved CNS penetration, are in clinical trials for recurrent HGG.
c-Met
Scatter factor/hepatocyte growth factor (SF/HGF) and its TKR c-Met play a role in cell growth, cell motility, morphogenesis and angiogenesis. 101 AMG 102 is a fully human monoclonal antibody that selectively targets SF/HGF. A phase II study of AMG 102 in recurrent GBM was recently completed but failed to produce any benefit. 102 A recent study suggests that the combination of EGFR inhibitors and c-Met inhibitors may be more effective than either agent alone in phosphatase and tensin homologue (PTEN) null GBM. 103 Trials of c-Met
TKIs such as XL184 are under way in GBM.
Intracellular Signalling Kinases
As activation of several RTKs, including EGFR and PDGFR, converges at the Ras/MAPK and PI3K/Akt pathways, inhibiting these downstream molecules may be more efficacious than targeting individual RTKs.
In the Ras/MAPK pathway, potential targets include Raf, MEK and farnesyltransferase. An early step in activation of the Ras/MAPK pathway is localisation of Ras to the cell membrane, which depends on Ras farnesylation by the enzyme farnesyltransferase. 
DNA Repair
Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme that signals the presence of DNA breaks and facilitates DNA repair by engaging mechanisms such as base excision repair (BER). 110 As PARP inhibitors disrupt BER, an important mediator of TMZ resistance, these agents may enhance the antitumour effects of temozolomide against HGG. Two PARP inhibitors, BSI-201 and ABT-888, are being tested in combination with radiation and temozolomide for newly diagnosed GBM.
Glioma Stem Cells
Glioma stem cells (GSCs) are believed to represent a subpopulation of cells in the tumour with the ability to self-renew, proliferate and give rise to progeny of multiple neuroepithelial lineages. 111 They may contribute to treatment resistance in HGG. 112, 113 Stem cells are predicted to be Advances in Treatment Options for High-grade Glioma Brain Trauma Oncology and vaccines against HSP90. 136 In small phase II studies, these vaccines appear to be well-tolerated and show promising efficacy compared with historic controls. However, larger prospective controlled studies will be required to confirm any clinical benefit. 
